Placement Agency Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Placement Agency Agreement (December 6th, 2017)

This letter (this "Agreement") constitutes the agreement between Biocept, Inc., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

THERMOGENESIS Corp. – Placement Agency Agreement (December 1st, 2017)

This letter (this "Agreement") constitutes the agreement between Cesca Therapeutics Inc., a Delaware corporation (the "Company"), and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson in placing the Securities.

Placement Agency Agreement (December 1st, 2017)

This letter (this "Agreement") constitutes the agreement between Pareteum Corp., a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

THERMOGENESIS Corp. – Placement Agency Agreement (November 29th, 2017)

This letter (this "Agreement") constitutes the agreement between Cesca Therapeutics Inc., a Delaware corporation (the "Company"), and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson in placing the Securities.

Leap Therapeutics, Inc. – Placement Agency Agreement (November 17th, 2017)
Bio-Path Holdings Inc – Placement Agency Agreement (November 6th, 2017)
PLACEMENT AGENCY AGREEMENT November 2, 2017 (November 3rd, 2017)
Soligenix Inc. – Placement Agency Agreement (October 31st, 2017)

Introduction. Subject to the terms and conditions herein (this "Agreement"), Soligenix,, Inc., a Delaware corporation (the "Company"), hereby agrees to sell up to an aggregate of Nine Hundred Eighty Two Thousand (982,000) shares of common stock (the "Shares"), par value $0.001 per share (the "Common Stock"), (the Shares or the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Aegis Capital Corp. (the "Placement Agent" and, each, a "Placement Agent"), as placement agent. The Shares shall be offered and sold pursuant to Section 4(a)(2) under the Securities Act (as hereinafter defined). The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a securities purchase agreement (the "Purchase Agreement"), shall be collectively referred to herein as the "Transaction Documents." The purchase price to the Investors for each Share is $2.00. The

Soligenix Inc. – Placement Agency Agreement (October 31st, 2017)

Introduction. Subject to the terms and conditions herein (this "Agreement"), Soligenix, Inc., a Delaware corporation (the "Company"), hereby agrees to sell up to an aggregate of One Million Five Hundred Seventy Five Thousand Five Hundred (1,575,500) shares of common stock (the "Shares"), par value $0.001 per share (the "Common Stock"), (the Shares or the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Aegis Capital Corp. (the "Placement Agent" and, each, a "Placement Agent"), as placement agent. The Shares shall be offered and sold under the Company's registration statement on Form S-3 (File No. 333-217738) with respect to the Shares. The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a securities purchase agreement (the "Purchase Agreement"), shall be collectively referred to herein as the "Transaction Documents." The purcha

Ocean Power Technologies – Placement Agency Agreement (October 19th, 2017)
Cellectar Biosciences, Inc. – Placement Agency Agreement (October 11th, 2017)

Introduction. Subject to the terms and conditions herein (this "Agreement"), Cellectar Biosciences, Inc., a Delaware corporation (the "Company"), hereby agrees to sell up to an aggregate of $7,770,000 of registered and unregistered securities (the "Securities") of the Company, including, but not limited to, shares (the "Shares") of the Company's common stock, par value $0.00001 per share (the "Common Stock"), shares of the Company's Series B convertible preferred stock, par value $0.00001 per share (the "Preferred Stock") and Common Stock purchase warrants (the " Warrants"; and, together with the Shares, the Preferred Stock and the Common Stock underlying the Warrants and Preferred Stock, the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Ladenburg Thalmann & Co. Inc., as placement agent ("Ladenburg" or the "Placement Agent"). The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on

Placement Agency Agreement (October 5th, 2017)

This letter (this "Agreement") constitutes the agreement between Pareteum Corporation, a Delaware corporation (the "Company") and Dawson James Securities, Inc. ("Dawson" or the "Placement Agent") pursuant to which Dawson shall serve as the exclusive placement agent (the "Services") for the Company, on a reasonable "best efforts" basis, in connection with the proposed offer and placement (the "Offering") by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawson's obligations hereunder are on a reasonable "best efforts" basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

Medical Transcription Billing, Corp – Placement Agency Agreement (September 21st, 2017)
Medical Transcription Billing, Corp – Placement Agency Agreement (September 6th, 2017)
Jin Jie – Placement Agency Agreement (August 17th, 2017)
15,656 Series B Convertible Preferred Shares Warrants to Purchase 2,345,427 Common Shares ALTIMMUNE, INC. Preferred Stock PLACEMENT AGENCY AGREEMENT (August 17th, 2017)
Q BioMed Inc. – Placement Agency Agreement (August 2nd, 2017)
Monaker Group, Inc. – MONAKER GROUP, INC. Placement Agency Agreement Common Stock and Warrants (August 1st, 2017)

This Placement Agency Agreement (the "Agreement") is entered into by and between Monaker Group, Inc., a Nevada corporation (the "Company"), and Northland Securities, Inc. (the "Agent") effective as of July 31, 2017. The Agreement supplements that certain letter agreement between the Company and Northland Securities, Inc. dated March 23, 2017 (the "Letter Agreement") by providing additional information with respect to the Private Placement (as defined below).

Jin Jie – Placement Agency Agreement (July 24th, 2017)
Placement Agency Agreement (June 30th, 2017)
DETERMINE, INC. 2,184,000 Shares of Common Stock PLACEMENT AGENCY AGREEMENT (June 21st, 2017)
Medical Transcription Billing, Corp – Placement Agency Agreement (June 20th, 2017)
Dipexium Pharmaceuticals, Inc. – Placement Agency Agreement (June 12th, 2017)
Guided Therapeutics, Inc. – Placement Agency Agreement (June 7th, 2017)
StemCells, Inc. – Placement Agency Agreement (June 6th, 2017)

Introduction. Subject to the terms and conditions herein (this "Agreement"), Microbot Medical, Inc., a Delaware corporation (the "Company"), hereby agrees to sell up to an aggregate of $10,500,000 of the Company's common stock, par value $0.01 per share (the "Common Stock" or the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through Ladenburg Thalmann & Co. Inc., as placement agent ("Ladenburg" or the "Placement Agent"). The Placement Agent may retain other brokers or dealers to act as sub-agents or selected-dealers on its behalf in connection with the Offering (as defined below).

Copytele – Placement Agency Agreement (May 17th, 2017)

This letter (this Agreement) constitutes the agreement between ITUS Corporation, a Delaware corporation (the Company) and Dawson James Securities, Inc. (Dawson or the Placement Agent) pursuant to which Dawson shall serve as the exclusive placement agent (the Services) for the Company, on a reasonable best efforts basis, in connection with the proposed offer and placement (the Offering) by the Company of its Securities (as defined Section 3 of this Agreement). The Company expressly acknowledges and agrees that Dawsons obligations hereunder are on a reasonable best efforts basis only and that the execution of this Agreement does not constitute a commitment by Dawson to purchase the Securities and does not ensure the successful placement of the Securities or any portion thereof or the success of Dawson placing the Securities.

Citius Pharmaceuticals, Inc. – PLACEMENT AGENCY AGREEMENT September 27, 2016 (May 15th, 2017)
Prime Meridian Holding Co – Prime Meridian Holding Company [] Shares of Common Stock, Par Value $0.01 Per Share Placement Agency Agreement (May 9th, 2017)
Aratana Therapeutics Inc. – ARATANA THERAPEUTICS, INC. Common Stock PLACEMENT AGENCY AGREEMENT (May 4th, 2017)

Aratana Therapeutics, Inc., a Delaware corporation (the "Company"), proposes to issue and sell to certain investors (each, an "Investor" and collectively, the "Investors") up to an aggregate of 5,000,000 shares (the "Shares") of the common stock, par value $0.001 per share, of the Company ("Common Stock"). Barclays Capital Inc. ("Barclays") has agreed to act as placement agent (the "Placement Agent") in connection with such issuance and sale of the Shares.

Placement Agency Agreement (April 24th, 2017)

Introduction. Subject to the terms and conditions herein (this Agreement), Marathon Patent Group, Inc., a Nevada corporation (the Company), hereby agrees to sell up to an aggregate of $2,660,000 of registered and unregistered securities of the Company, including, but not limited to, 3,800,000 shares of common stock (the Shares), par value $0.0001 per share (the Common Stock), and Common Stock purchase warrants to purchase up to an aggregate of 2,280,000 shares of Common Stock (the Warrants and, together with the Shares, the Securities) directly to various investors (each, an Investor and, collectively, the Investors) through Aegis Capital Corp. (the Placement Agent and, each, a Placement Agent), as placement agent. The Shares shall be offered and sold under the Companys registration statement on Form S-3 (File No. 333-198569) with respect to the Shares and pursuant to Section 4(a)(2) under the Securities Act (as hereinafter defined), with respect to the Warrants. The documents execute

Nxt-ID, Inc. – Nxt-Id, Inc. Placement Agency Agreement Common Stock and Warrants (April 14th, 2017)
Akers Biosciences Inc – Placement Agency Agreement (April 5th, 2017)
Ekso Bionics Holdings, Inc. – PLACEMENT AGENCY AGREEMENT April 2, 2017 (April 5th, 2017)

Introduction. Subject to the terms and conditions herein (this "Agreement"), Ekso Bionics Holdings, Inc., a Nevada corporation (the "Company"), hereby agrees to sell up to an aggregate of $11,720,000 of registered securities of the Company consisting of shares (the "Shares") of the Company's common stock, $0.001 par value per share (the "Common Stock"), and warrants to purchase shares of Common Stock (the "Warrants" and the shares of Common Stock issuable upon exercise of the Warrants, the "Warrant Shares", and the Shares, the Warrants, and the Warrant Shares, collectively, the "Securities") directly to various investors (each, an "Investor" and, collectively, the "Investors") through B. Riley & Co., LLC, as placement agent (the "Placement Agent"). The documents executed and delivered by the Company and the Investors in connection with the Offering (as defined below), including, without limitation, a securities purchase agreement (the "Purchase Agreement"), shall be collectively referr

Placement Agency Agreement (March 30th, 2017)
PLACEMENT AGENCY AGREEMENT March 8, 2017 (March 22nd, 2017)